Open-label study to determine how prior therapy with alendronate [alendronic acid] or risedronate [risedronic acid] in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide.

Trial Profile

Open-label study to determine how prior therapy with alendronate [alendronic acid] or risedronate [risedronic acid] in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms OPTAMISE
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jul 2011 Additional trial location (Germany) added as reported by European Clinical Trials Database.
    • 12 Jul 2011 New source added and integrated (European Clinical Trials Database, EudraCT2004-002317-37).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top